Global Dengue Vaccine Market 2017-2021

  • ID: 4432779
  • Report
  • Region: Global
  • 78 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • GeneOne Life Sciences
  • GlaxoSmithKline
  • Medigen Biologics
  • Merck Sharp & Dohme
  • Panacea Biotec
  • Sanofi
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Dengue Vaccine

The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.

The analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global dengue vaccine market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Dengue Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi
  • Takeda Pharmaceuticals
Other prominent vendors
  • GeneOne Life Sciences
  • Medigen Biologics
  • Panacea Biotec
  • Sun Pharmaceutical
Market drivers
  • Rapid growth in disease prevalence
  • For a full, detailed list, view the full report
Market challenges
  • Regulatory hurdles in vaccine penetration
  • For a full, detailed list, view the full report
Market trends
  • Licensing deals
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GeneOne Life Sciences
  • GlaxoSmithKline
  • Medigen Biologics
  • Merck Sharp & Dohme
  • Panacea Biotec
  • Sanofi
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Market overview
  • Market size and forecast
PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE ANALYSIS

PART 08: MARKET SEGMENTATION BY END-USER
  • Government institutions
  • Hospitals
  • NGOs
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
  • Live attenuated vaccines
  • Inactivated vaccines
PART 10: REGIONAL LANDSCAPE
  • Regional comparison
  • Dengue vaccine market in Americas
  • Dengue vaccine market in EMEA
  • Dengue vaccine market in APAC
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Licensing deals
  • Growing awareness
  • Advances in diagnostic techniques
  • Novel approach to eliminate dengue
PART 14: VENDOR LANDSCAPE

PART 15: KEY VENDOR ANALYSIS
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi Pasteur
  • Takeda Pharmaceuticals
  • Other prominent vendors
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Forms of dengue
Exhibit 02: Transmission cycle of dengue infection
Exhibit 03: Global dengue vaccine market: Snapshot
Exhibit 04: Global dengue vaccine market: Segmentation
Exhibit 05: Global dengue vaccine market 2016-2021 ($ millions)
Exhibit 06: Global dengue vaccine market: Opportunity analysis
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline landscape by development phase
Exhibit 09: Key clinical trials
Exhibit 10: Global dengue vaccine market share by end-user 2016
Exhibit 11: Global dengue vaccine market share by end-user 2021
Exhibit 12: Global dengue vaccine market by government institutions 2016-2021 ($ millions)
Exhibit 13: Global dengue vaccine market by hospitals 2016-2021 ($ millions)
Exhibit 14: Global dengue vaccine market by NGOs 2016-2021 ($ millions)
Exhibit 15: Types of dengue vaccine
Exhibit 16: Licensing of TV003 and TV005 by NIAID
Exhibit 17: Global dengue vaccine market by region 2016-2021
Exhibit 18: Regional comparison
Exhibit 19: Dengue vaccine market in Americas 2016-2021 ($ millions)
Exhibit 20: Dengue vaccine market in Americas: Year over year growth
Exhibit 21: Dengue vaccine market in EMEA 2016-2021 ($ millions)
Exhibit 22: Dengue vaccine market in EMEA: Year over year growth
Exhibit 23: Dengue vaccine market in APAC 2016-2021 ($ millions)
Exhibit 24: Dengue vaccine market in APAC: Year over year growth
Exhibit 25: Vaccines in global dengue vaccine market
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck Sharp & Dohme: Key highlights
Exhibit 31: Merck Sharp & Dohme: Strength assessment
Exhibit 32: Merck Sharp & Dohme: Strategy assessment
Exhibit 33: Merck Sharp & Dohme: Opportunity assessment
Exhibit 34: Sanofi Pasteur: Key highlights
Exhibit 35: Sanofi Pasteur: Strength assessment
Exhibit 36: Sanofi Pasteur: Strategy assessment
Exhibit 37: Sanofi Pasteur: Opportunity assessment
Exhibit 38: Takeda Pharmaceuticals: Key highlights
Exhibit 39: Takeda Pharmaceuticals: Strength assessment
Exhibit 40: Takeda Pharmaceuticals: Strategy assessment
Exhibit 41: Takeda Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • GeneOne Life Sciences
  • GlaxoSmithKline
  • Medigen Biologics
  • Merck Sharp & Dohme
  • Panacea Biotec
  • Sanofi
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: – Global Dengue Vaccine Market 2017-2021

The author of the report recognizes the following companies as the key players in the global dengue vaccine market: GlaxoSmithKline, Merck Sharp & Dohme, Sanofi, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, and Sun Pharmaceutical.

Commenting on the report, an analyst from the research team said: “One trend in the market is licensing deals. Companies are increasingly focused on developing novel and effective dengue vaccines. Toward that effort, they are engaging in partnerships and collaborations with other market players. Several licensing deals have taken place in the global dengue vaccine market.”

According to the report, one driver in the market is rapid growth in disease prevalence. The prevalence of dengue is rising rapidly. The factors contributing to the rise in dengue cases include an increase in population density and global warming. As per the NIH, 3.6 billion people that reside in tropical and subtropical regions are at risk of dengue transmission. Global estimates vary, but nearly 0.05 to 0.2 billion cases of dengue infections are reported annually. In 2011, annual cases of severe dengue were around 0.5 million, and mortality due to dengue was above 20,000 as per the NIH. As per the NIH, in 2012, the upper bound total was 3.97 billion for people at risk of dengue in 128 countries globally.

Further, the report states that one challenge in the market is regulatory hurdles in vaccine penetration. Vendors are facing difficulty in getting approvals for the launch of vaccines in several dengue-endemic countries due to the nature of dengue serotypes in different countries. The circulation of dengue serotypes fluctuates in dengue-endemic regions. Hence, vaccine efficacy must be exhibited against all four serotypes for which region-specific clinical trials are required to be conducted. For the inclusion of vaccines in the public immunization program of any country, demographic efficacy and safety data are required, which require additional clinical trials at regional levels at times to comply with the regulatory requirements. This leads to delay in the launch of the product, and ultimately the potential sales get affected negatively.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi
  • Takeda Pharmaceuticals
  • GeneOne Life Sciences
  • Medigen Biologics
  • Panacea Biotec
  • Sun Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll